GUJARAT THEMIS BIOSYN Latest Share Price (GUJTHEM)
TODAY IN ONE LINE
GUJTHEM dropped 4.0% on light volume, lagging Nifty's -1.1% move, with no exchange filing today, suggesting a market-driven move.
With a market cap of ₹4,665.94 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GUJARAT THEMIS BIOSYN flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Strong Return on EquityHealthy ROE of 16.2%
- ●Healthy Operating MarginsOPM is structurally strong at 39.2%
- ●High Promoter HoldingPromoters hold 70.9% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 9.1% YoY
- ●Rising Receivables vs SalesReceivables grew 13.4% outpacing sales growth of -11.2%
Latest GUJARAT THEMIS BIOSYN News
What changed recently?
Recent events, corporate actions, and announcements.
GUJARAT THEMIS BIOSYN valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GUJARAT THEMIS BIOSYN, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GUJARAT THEMIS BIOSYN technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for GUJARAT THEMIS BIOSYN — derived from the latest tape, not yesterday's close.
GUJARAT THEMIS BIOSYN last traded at ₹358.65 with an intraday range of ₹357–₹372.2 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹358.65| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 398.63 | +39.98 | +11.15% |
| R3 | 383.43 | +24.78 | +6.91% |
| R2 | 377.82 | +19.17 | +5.34% |
| R1 | 368.23 | +9.58 | +2.67% |
| PIVOT | 362.62 | 3.97 | 1.11% |
| CURRENT | 358.65 | — | — |
| S1 | 353.03 | -5.62 | -1.57% |
| S2 | 347.42 | -11.23 | -3.13% |
| S3 | 337.83 | -20.82 | -5.80% |
| S4 | 322.63 | -36.02 | -10.04% |
GUJTHEM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹366.3–₹372.2
Trading Below opening range, showing Bearishness
GUJARAT THEMIS BIOSYN financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GUJARAT THEMIS BIOSYN — consolidated or standalone — with margins, YoY growth and key ratios inline.
GUJARAT THEMIS BIOSYN reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,665.94 Cr. and reported EPS of ₹1.02.
GUJARAT THEMIS BIOSYN segment analysis : revenue and profit mix.
Disclosed business segments at GUJARAT THEMIS BIOSYN with their share of revenue and profit, switchable between consolidated and standalone reporting.
GUJARAT THEMIS BIOSYN discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GUJARAT THEMIS BIOSYN.
Our AI distills the core fundamental drivers supporting GUJARAT THEMIS BIOSYN, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GUJARAT THEMIS BIOSYN's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. Bedrock invocation timeout
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.06. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 11% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.10%.
GUJARAT THEMIS BIOSYN peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GUJARAT THEMIS BIOSYN is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GUJARAT THEMIS BIOSYN chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GUJARAT THEMIS BIOSYN — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
GUJARAT THEMIS BIOSYN delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GUJARAT THEMIS BIOSYN over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GUJARAT THEMIS BIOSYN stood at 62.8% of traded volume, against a 20-day average of 56.0%.
GUJARAT THEMIS BIOSYN announcements: results, concalls, ratings, M&A.
Filings GUJARAT THEMIS BIOSYN sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GUJARAT THEMIS BIOSYN files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 131 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Gujarat Themis Biosyn Limited has informed the Exchange about Certificate under 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for…
Credit Rating
Gujarat Themis Biosyn Limited has informed the Exchange about Credit Rating
Shareholders meeting
Scrutinizer's Report of 45th Annual General Meeting of the Company counter signed by the Chairman.
Shareholders meeting
Gujarat Themis Biosyn Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 30, 2026. Further,…
Shareholders meeting
Revised outcome of 45th Annual General Meeting of the Company due to typographical error.
Investor decks & rating reports.
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation
Investor Presentation
Investor Presentation
GUJARAT THEMIS BIOSYN dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GUJARAT THEMIS BIOSYN has declared, sequenced by announce and record date.
GUJARAT THEMIS BIOSYN corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About GUJARAT THEMIS BIOSYN: business, sector, key facts.
What GUJARAT THEMIS BIOSYN does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GUJARAT THEMIS BIOSYN operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GUJTHEM, BSE: 506879.
Gujarat Themis Biosyn Limited (GUJTHEM) is an Indian pharmaceutical company specializing in the manufacturing of pharmaceuticals and medicinal chemicals. Its primary operations are focused within India, contributing to the domestic pharmaceutical market.
A significant part of GUJTHEM's business model involves providing bulk drug manufacturing services on a job work basis. This means the company produces active pharmaceutical ingredients (APIs) for other pharmaceutical companies, acting as a contract manufacturer rather than solely focusing on producing and selling its own branded products. This outsourcing model allows GUJTHEM to leverage its manufacturing capabilities to serve a broader range of clients.
The company's product portfolio includes several key APIs, highlighting its expertise in specific therapeutic areas. Rifamycin-S, an intermediate used in the creation of tuberculosis treatments, is a prominent example. The production of Rifamycin-O, another important intermediate, also features prominently. Lovastatin, a cholesterol-lowering drug, represents another significant product within GUJTHEM's range. This diverse product mix showcases the company's capabilities in producing different types of APIs for various pharmaceutical applications.
Established in 1981 and headquartered in Mumbai, GUJTHEM has a long history in the Indian pharmaceutical industry. Its long operational history suggests a degree of experience and established manufacturing processes. The location in Mumbai positions it strategically within a major economic and industrial hub of India, facilitating access to resources, talent, and markets.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- 3B BLACKBIO DX (3BBLACKBIO) Share PricePeer
- ABBOTT INDIA (ABBOTINDIA) Share PricePeer
- ACUTAAS CHEMICALS (ACUTAAS) Share PricePeer
- ANLON HEALTHCARE (AHCL) Share PricePeer
- AMANTA (AMANTA) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GUJARAT THEMIS BIOSYN (GUJTHEM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GUJARAT THEMIS BIOSYN (GUJTHEM)?
The current share price of GUJARAT THEMIS BIOSYN (GUJTHEM) is ₹358.65. Today, the stock has declined by ₹14.75 (3.95%), trading in a range of ₹357.00 to ₹372.20. The stock opened at ₹367.65 with a trading volume of 89,208 shares.
02Is GUJARAT THEMIS BIOSYN stock a good investment for long-term?
GUJARAT THEMIS BIOSYN can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,665.94 Cr., P/E ratio of 0, ROE of 16.22%, and ROCE of 11.12%. The dividend yield stands at 0.19%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GUJARAT THEMIS BIOSYN stock?
The 52-week high price of GUJARAT THEMIS BIOSYN (GUJTHEM) is ₹479.00, while the 52-week low is ₹225.05. Currently trading at ₹358.65, the stock is 59.36% above its 52-week low and 25.13% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GUJARAT THEMIS BIOSYN stock at the current price?
Whether to buy GUJARAT THEMIS BIOSYN stock at ₹358.65 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a loss of 3.95%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GUJARAT THEMIS BIOSYN and when is the next dividend?
GUJARAT THEMIS BIOSYN offers a dividend yield of 0.19%, which means for every ₹100 invested at the current price of ₹358.65, you can expect to receive approximately ₹0.19 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GUJARAT THEMIS BIOSYN?
GUJARAT THEMIS BIOSYN's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0, ROE: 16.22%, ROCE: 11.12%, Dividend Yield: 0.19%, EPS: ₹1.02, Book Value: ₹26.41, and Debt-to-Equity: 0.56. The company's market cap stands at ₹4,665.94 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GUJARAT THEMIS BIOSYN stock performing today in the market?
GUJARAT THEMIS BIOSYN stock opened at ₹367.65 and is currently trading at ₹358.65, showing a decline of ₹14.75 (3.95%). The intraday high is ₹372.20 and low is ₹357.00. The trading volume stands at 89,208 shares, indicating moderate market participation today.
08What is the P/E ratio of GUJARAT THEMIS BIOSYN and what does it indicate?
GUJARAT THEMIS BIOSYN has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹1.02, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GUJARAT THEMIS BIOSYN (GUJTHEM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.